Identification of differentially expressed genes according to chemosensitivity in advanced ovarian serous adenocarcinomas: Expression of GRIA2 predicts better survival

British Journal of Cancer

Volumn 107, Issue 1, 2012, Pages 91-99

  Choi, C H ^a   Choi, J J ^a   Park, Y A ^a   Lee, Y Y ^a   Song, S Y ^a   Sung, C O ^b   Song, T ^c   Kim, M K ^a   Kim, T J ^a   Lee, J W ^a   Kim, H J ^a   Bae, D S ^a   Kim, B G ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c CHA University   (South Korea)

Author keywords

Gene expression profiling; GRIA2; microarray; ovarian serous adenocarcinoma; survival

Indexed keywords

BIOLOGICAL MARKER; CD36 ANTIGEN; CISPLATIN DERIVATIVE; IMMUNOGLOBULIN FC FRAGMENT; LEUKEMIA INHIBITORY FACTOR RECEPTOR ALPHA; PROTEIN CHL1; PROTEIN GRIA2; TAXANE DERIVATIVE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; OVARY ADENOCARCINOMA; OVERALL SURVIVAL; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

ADULT; AGED; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; RECEPTORS, AMPA;

EID: 84862981130     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.217     Document Type: Article

References (43)

1. Abdul M, Hoosein N (2005) N-methyl-D-aspartate receptor in human prostate cancer. J Membr Biol 205: 125-128 (Pubitemid 41803689)
2. Bachvarov D, L'Esperance S, Popa I, Bachvarova M, Plante M, Tetu B (2006) Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy. Int J Oncol 29: 919-933
3. Behar TN, Scott CA, Greene CL, Wen X, Smith SV, Maric D, Liu QY, Colton CA, Barker JL (1999) Glutamate acting at NMDA receptors stimulates embryonic cortical neuronal migration. J Neurosci 19: 4449-4461 (Pubitemid 29241096)
4. Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, Murphy S, Dressman HK, Febbo PG, West M, Nevins JR, Marks JR (2005) Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers. Clin Cancer Res 11: 3686-3696 (Pubitemid 40685585)
5. Beretta F, Bassani S, Binda E, Verpelli C, Bello L, Galli R, Passafaro M (2009) The GluR2 subunit inhibits proliferation by inactivating Src-MAPK signalling and induces apoptosis by means of caspase 3/6-dependent activation in glioma cells. Eur J Neurosci 30: 25-34
6. Cancer Genome Atlas Research Network (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474: 609-615
7. Collins Y, Tan DF, Pejovic T, Mor G, Qian F, Rutherford T, Varma R, McQuaid D, Driscoll D, Jiang M, Deeb G, Lele S, Nowak N, Odunsi K (2004) Identification of differentially expressed genes in clinically distinct groups of serous ovarian carcinomas using cDNA microarray. Int J Mol Med 14: 43-53
8. du Bois A, Luck HJ, Meier W, Adams HP, Mobus V, Costa S, Bauknecht T, Richter B, Warm M, Schroder W, Olbricht S, Nitz U, Jackisch C, Emons G, Wagner U, Kuhn W, Pfisterer J (2003) A randomized clinical trial of cisplatin/paclitaxel vs carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 95: 1320-1329
9. Dupuy A, Simon RM (2007) Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. J Natl Cancer Inst 99: 147-157
10. Greathouse KL, Cook JD, Lin K, Davis BJ, Berry TD, Bredfeldt TG, Walker CL (2008) Identification of uterine leiomyoma genes developmentally reprogrammed by neonatal exposure to diethylstilbestrol. Reprod Sci 15: 765-778
11. Hansen KB, Yuan H, Traynelis SF (2007) Structural aspects of AMPA receptor activation, desensitization and deactivation. Curr Opin Neurobiol 17: 281-288 (Pubitemid 46880320)
12. Hartmann LC, Lu KH, Linette GP, Cliby WA, Kalli KR, Gershenson D, Bast RC, Stec J, Iartchouk N, Smith DI, Ross JS, Hoersch S, Shridhar V, Lillie J, Kaufmann SH, Clark EA, Damokosh AI (2005) Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res 11: 2149-2155 (Pubitemid 40490171)
13. Herner A, Sauliunaite D, Michalski CW, Erkan M, De Oliveira T, Abiatari I, Kong B, Esposito I, Friess H, Kleeff J (2011) Glutamate increases pancreatic cancer cell invasion and migration via AMPA receptor activation and Kras-MAPK signaling. Int J Cancer 129: 2349-2359
14. Hollmann M, Heinemann S (1994) Cloned glutamate receptors. Annu Rev Neurosci 17: 31-108 (Pubitemid 24117025)
15. Huang da W, Sherman BT, Lempicki RA (2009a) Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res 37: 1-13
16. Huang da W, Sherman BT, Lempicki RA (2009b) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4: 44-57
17. Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, Dikranian K, Tenkova TI, Stefovska V, Turski L, Olney JW (1999) Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283: 70-74 (Pubitemid 29044848)
18. International Collaborative Ovarian Neoplasm Group (2002) Paclitaxel plus carboplatin vs standard chemotherapy with either singleagent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 360: 505-515
19. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264
20. Ishiuchi S, Yoshida Y, Sugawara K, Aihara M, Ohtani T, Watanabe T, Saito N, Tsuzuki K, Okado H, Miwa A, Nakazato Y, Ozawa S (2007) Ca2+ permeable AMPA receptors regulate growth of human glioblastoma via Akt activation. J Neurosci 27: 7987-8001 (Pubitemid 47173326)
21. Joo JY, Kim BW, Lee JS, Park JY, Kim S, Yun YJ, Lee SH, Rhim H, Son H (2007) Activation of NMDA receptors increases proliferation and differentiation of hippocampal neural progenitor cells. J Cell Sci 120: 1358-1370 (Pubitemid 46780029)
22. Kim CJ, Lee JW, Choi JJ, Choi HY, Park YA, Jeon HK, Sung CO, Song SY, Lee YY, Choi CH, Kim TJ, Lee JH, Kim BG, Bae DS (2010) High claudin-7 expression is associated with a poor response to platinum-based chemotherapy in epithelial ovarian carcinoma. Eur J Cancer 47: 918-925
23. Koch CM, Wagner W (2011) Epigenetic-aging-signature to determine age in different tissues. Aging 3: 1018-1027
24. Konstantinopoulos PA, Spentzos D, Cannistra SA (2008) Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol 5: 577-587
25. Lancaster JM, Dressman HK, Whitaker RS, Havrilesky L, Gray J, Marks JR, Nevins JR, Berchuck A (2004) Gene expression patterns that characterize advanced stage serous ovarian cancers. J Soc Gynecol Investig 11: 51-59 (Pubitemid 38050192)
26. Lee JW, Choi CH, Choi JJ, Park YA, Kim SJ, Hwang SY, Kim WY, Kim TJ, Lee JH, Kim BG, Bae DS (2008) Altered MicroRNA expression in cervical carcinomas. Clin Cancer Res 14: 2535-2542
27. Leja J, Essaghir A, Essand M, Wester K, Oberg K, Totterman TH, Lloyd R, Vasmatzis G, Demoulin JB, Giandomenico V (2009) Novel markers for enterochromaffin cells and gastrointestinal neuroendocrine carcinomas. Mod Pathol 22: 261-272
28. Michalski CW, Oti FE, Erkan M, Sauliunaite D, Bergmann F, Pacher P, Batkai S, Muller MW, Giese NA, Friess H, Kleeff J (2008) Cannabinoids in pancreatic cancer: correlation with survival and pain. Int J Cancer 122: 742-750
29. Mok SC, Bonome T, Vathipadiekal V, Bell A, Johnson ME, Wong KK, Park DC, Hao K, Yip DK, Donninger H, Ozbun L, Samimi G, Brady J, Randonovich M, Pise-Masison CA, Barrett JC, Wong WH, Welch WR, Berkowitz RS, Birrer MJ (2009) A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibrilassociated glycoprotein 2. Cancer Cell 16: 521-532
30. Ouellet V, Guyot MC, Le Page C, Filali-Mouhim A, Lussier C, Tonin PN, Provencher DM, Mes-Masson AM (2006) Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer 119: 599-607 (Pubitemid 43955714)
31. Rao VR, Finkbeiner S (2007) NMDA and AMPA receptors: old channels, new tricks. Trends Neurosci 30: 284-291 (Pubitemid 46802833)
32. Runnebaum IB, Stickeler E (2001) Epidemiological and molecular aspects of ovarian cancer risk. J Cancer Res Clin Oncol 127: 73-79
33. Rzeski W, Turski L, Ikonomidou C (2001) Glutamate antagonists limit tumor growth. Proc Natl Acad Sci USA 98: 6372-6377 (Pubitemid 32488244)
34. Saeed AI, Bhagabati NK, Braisted JC, Liang W, Sharov V, Howe EA, Li J, Thiagarajan M, White JA, Quackenbush J (2006) TM4 microarray software suite. Methods Enzymol 411: 134-193
35. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, Sturn A, Snuffin M, Rezantsev A, Popov D, Ryltsov A, Kostukovich E, Borisovsky I, Liu Z, Vinsavich A, Trush V, Quackenbush J (2003) TM4: a free, open-source system for microarray data management and analysis. Biotechniques 34: 374-378 (Pubitemid 36184095)
36. Seeburg PH (1993) The TiPS/TINS lecture: the molecular biology of mammalian glutamate receptor channels. Trends Pharmacol Sci 14: 297-303 (Pubitemid 23242582)
37. Senchenko VN, Krasnov GS, Dmitriev AA, Kudryavtseva AV, Anedchenko EA, Braga EA, Pronina IV, Kondratieva TT, Ivanov SV, Zabarovsky ER, Lerman MI (2011) Differential expression of CHL1 gene during development of major human cancers. PLoS One 6: e15612
38. Spentzos D, Levine DA, Ramoni MF, Joseph M, Gu X, Boyd J, Libermann TA, Cannistra SA (2004) Gene expression signature with independent prognostic significance in epithelial ovarian cancer. J Clin Oncol 22: 4700-4710
39. Takeda M, Haga M, Yamada H, Kinoshita M, Otsuka M, Tsuboi S, Moriyama Y (2000) Ionotropic glutamate receptors expressed in human retinoblastoma Y79 cells. Neurosci Lett 294: 97-100
40. Trinh XB, Tjalma WA, Dirix LY, Vermeulen PB, Peeters DJ, Bachvarov D, Plante M, Berns EM, Helleman J, Van Laere SJ, van Dam PA (2011) Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma. PLoS One 6: e22469
41. Tsibris JC, Maas S, Segars JH, Nicosia SV, Enkemann SA, O'Brien WF, Spellacy WN (2003) New potential regulators of uterine leiomyomata from DNA arrays: the ionotropic glutamate receptor GluR2. Biochem Biophys Res Commun 312: 249-254 (Pubitemid 37443953)
42. Wolterink S, Moldenhauer G, Fogel M, Kiefel H, Pfeifer M, Luttgau S, Gouveia R, Costa J, Endell J, Moebius U, Altevogt P (2010) Therapeutic antibodies to human L1CAM: functional characterization and application in a mouse model for ovarian carcinoma. Cancer Res 70: 2504-2515
43. Yoshioka A, Ikegaki N, Williams M, Pleasure D (1996) Expression of N-methyl-D-aspartate (NMDA) and non-NMDA glutamate receptor genes in neuroblastoma, medulloblastoma, and other cells lines. J Neurosci Res 46: 164-178